{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:09:24Z","timestamp":1778609364405,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["2020-5806\/CMB\/ADHOC\/BMS"],"award-info":[{"award-number":["2020-5806\/CMB\/ADHOC\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["2021-12413\/CMB-BMS"],"award-info":[{"award-number":["2021-12413\/CMB-BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/09\/IYBA\/2015\/10"],"award-info":[{"award-number":["BT\/09\/IYBA\/2015\/10"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ajpath.2024.05.006","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T13:14:29Z","timestamp":1718284469000},"page":"1780-1798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aurora Kinase A Is Overexpressed in Human Retinoblastoma and Correlates with Histopathologic High-Risk Factors"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0191-400X","authenticated-orcid":false,"given":"Naheed Arfin","family":"Borah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumya","family":"Sucharita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suryasnata","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-9961","authenticated-orcid":false,"given":"Swathi","family":"Kaliki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devjyoti","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3492-4661","authenticated-orcid":false,"given":"Mamatha M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2024.05.006_bib1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/bjo.2008.150292","article-title":"The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death","volume":"93","author":"Kivel\u00e4","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ceo.12132","article-title":"Review: the genomic landscape of retinoblastoma: a review","volume":"42","author":"Th\u00e9riault","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4103\/0301-4738.97077","article-title":"Distant metastatic retinoblastoma without central nervous system involvement","volume":"61","author":"Ali","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.05.005","article-title":"Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace: \u201calive, with good vision and no comorbidity.\u201d","volume":"73","author":"Munier","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib5","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/hmg\/ddn024","article-title":"Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma","volume":"17","author":"Dimaras","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajpath.2024.05.006_bib6","article-title":"Retinoblastoma","volume":"1","author":"Dimaras","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ajpath.2024.05.006_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature05194","article-title":"Inactivation of the p53 pathway in retinoblastoma","volume":"444","author":"Laurie","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.05.006_bib8","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.3390\/cancers13205248","article-title":"The oncogene MYCN modulates glycolytic and invasive genes to enhance cell viability and migration in human retinoblastoma","volume":"13","author":"Sradhanjali","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.05.006_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200721119","article-title":"An immature, dedifferentiated, and lineage-deconstrained cone precursor origin of N-Myc\u2013initiated retinoblastoma","volume":"119","author":"Singh","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.05.006_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(13)70045-7","article-title":"Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies","volume":"14","author":"Rushlow","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cmet.2015.09.003","article-title":"MYC disrupts the circadian clock and metabolism in cancer cells","volume":"22","author":"Altman","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2024.05.006_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/2159-8290.CD-17-0273","article-title":"The expanding world of N-MYC-driven tumors","volume":"8","author":"Rickman","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.05.006_bib13","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1038\/s41467-022-33248-2","article-title":"Characterizing DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.05.006_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","article-title":"Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma","volume":"15","author":"Otto","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.05.006_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div"},{"key":"10.1016\/j.ajpath.2024.05.006_bib16","doi-asserted-by":"crossref","first-page":"23937","DOI":"10.18632\/oncotarget.14893","article-title":"Aurora kinases: novel therapy targets in cancers","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajpath.2024.05.006_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2014.14","article-title":"The aurora kinases in cell cycle and leukemia","volume":"34","author":"Goldenson","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2024.05.006_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1107\/S2059798322011433","article-title":"Crystal structure of a covalently linked Aurora-A-MYCN complex","volume":"79","author":"Diebold","year":"2023","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","article-title":"Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.05.006_bib20","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.apsb.2023.03.013","article-title":"Emerging roles of Aurora-A kinase in cancer therapy resistance","volume":"13","author":"Zheng","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ajpath.2024.05.006_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1167\/iovs.62.3.16","article-title":"Aurora kinase B expression, its regulation and therapeutic targeting in human retinoblastoma","volume":"62","author":"Borah","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2024.05.006_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13000-014-0221-9","article-title":"Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review","volume":"9","author":"Fedchenko","year":"2014","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172358","article-title":"Assessing mycoplasma contamination of cell cultures by qPCR using a set of universal primer pairs targeting a 1.5 kb fragment of 16S rRNA genes","volume":"12","author":"Jean","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2024.05.006_bib24","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","article-title":"A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma","volume":"115","author":"G\u00f6rg\u00fcn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2024.05.006_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fonc.2015.00285","article-title":"A cell biologist's field guide to aurora kinase inhibitors","volume":"5","author":"de Groot","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4161\/cc.11.4.19323","article-title":"The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent","volume":"11","author":"Nair","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ajpath.2024.05.006_bib27","doi-asserted-by":"crossref","first-page":"D933","DOI":"10.1093\/nar\/gkac958","article-title":"Ensembl 2023","volume":"51","author":"Martin","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib28","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/0008-5472.CAN-10-4391","article-title":"A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma","volume":"71","author":"Shohet","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib29","first-page":"D65","article-title":"EPD in 2020: enhanced data visualization and extension to ncRNA promoters","volume":"48","author":"Meylan","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib30","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1093\/nar\/gku1111","article-title":"The Eukaryotic Promoter Database: expansion of EPDnew and new promoter analysis tools","volume":"43","author":"Dreos","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib31","article-title":"The in ovo chick chorioallantoic membrane (CAM) assay as an efficient xenograft model of hepatocellular carcinoma","volume":"9","author":"Li","year":"2015","journal-title":"J Vis Exp"},{"key":"10.1016\/j.ajpath.2024.05.006_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215312","article-title":"Optimization of the chicken chorioallantoic membrane assay as reliable in\u00a0vivo model for the analysis of osteosarcoma","volume":"14","author":"Kunz","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2024.05.006_bib33","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1021\/acsptsci.1c00083","article-title":"A standard protocol for the production and bioevaluation of ethical in\u00a0vivo models of HPV-negative head and neck squamous cell carcinoma","volume":"4","author":"Sarogni","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.ajpath.2024.05.006_bib34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17425255.2021.1879047","article-title":"Tumor grafted - chick chorioallantoic membrane as an alternative model for biological cancer research and conventional\/nanomaterial-based theranostics evaluation","volume":"17","author":"Mapanao","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaophthalmol.2021.4732","article-title":"Defining high-risk retinoblastoma: a multicenter global survey","volume":"140","author":"Kaliki","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng1279","article-title":"Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53","volume":"36","author":"Katayama","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2024.05.006_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/ceo.12517","article-title":"Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters","volume":"43","author":"Singh","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature07185","article-title":"Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery","volume":"455","author":"Mac\u016frek","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.05.006_bib39","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood-2009-11-251074","article-title":"Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state","volume":"116","author":"den Hollander","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2024.05.006_bib40","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1093\/nar\/gnh091","article-title":"RNAPol-ChIP: a novel application of chromatin immunoprecipitation to the analysis of real-time gene transcription","volume":"32","author":"Sandoval","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2024.05.006_bib42","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1038\/s41467-019-13485-8","article-title":"Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.05.006_bib43","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1541-7786.MCR-19-1226","article-title":"Inhibition of Aurora-A promotes CD8+ T-cell infiltration by mediating IL10 production in cancer cells","volume":"18","author":"Han","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/2159-8290.CD-18-0389","article-title":"Cells lacking the RB1 tumor suppressor gene are hyperdependent on Aurora B kinase for survival","volume":"9","author":"Oser","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.05.006_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2010.03.019","article-title":"Specific killing of Rb mutant cancer cells by inactivating TSC2","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.05.006_bib46","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1158\/0008-5472.CAN-16-3299","article-title":"SKP2 activation by thyroid hormone receptor [beta]2 bypasses Rb-dependent proliferation in Rb-deficient cells","volume":"77","author":"Xu","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib47","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s12276-021-00635-6","article-title":"a synthetic lethal target for precision cancer medicine","volume":"53","author":"Mou","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ajpath.2024.05.006_bib48","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/molecules26071981","article-title":"Aurora kinase B inhibition: a potential therapeutic strategy for cancer","volume":"26","author":"Borah","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ajpath.2024.05.006_bib49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fonc.2016.00247","article-title":"Functional significance of Aurora kinases-p53 protein family interactions in cancer","volume":"6","author":"Sasai","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2024.05.006_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100188","article-title":"High-level MYCN-amplified RB1-proficient retinoblastoma tumors retain distinct molecular signatures","volume":"2","author":"Roohollahi","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajpath.2024.05.006_bib52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.05.006_bib53","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/0008-5472.CAN-19-1479","article-title":"Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes with navitoclax to induce rhabdomyosarcoma cell death","volume":"80","author":"Ommer","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.05.006_bib54","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/1568026618666180523105756","article-title":"Inhibition of pyruvate dehydrogenase kinase as a therapeutic strategy against cancer","volume":"18","author":"Sradhanjali","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ajpath.2024.05.006_bib55","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3390\/cancers15072144","article-title":"Lipid metabolic reprogramming in embryonal neoplasms with MYCN amplification","volume":"15","author":"Talapatra","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2024.05.006_bib56","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1124\/pharmrev.122.000795","article-title":"The Myc family and the metastasis suppressor NDRG1: targeting key molecular interactions with innovative therapeutics","volume":"75","author":"Deng","year":"2023","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ajpath.2024.05.006_bib57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccr.2014.07.015","article-title":"Drugging MYCN through an allosteric transition in Aurora kinase A","volume":"26","author":"Gustafson","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.05.006_bib58","doi-asserted-by":"crossref","first-page":"13836","DOI":"10.1073\/pnas.1008366107","article-title":"Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2024.05.006_bib59","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ccell.2020.01.001","article-title":"Direct phosphorylation and stabilization of MYC by Aurora B kinase promote T-cell leukemogenesis","volume":"37","author":"Jiang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.05.006_bib60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/kjm2.12469","article-title":"Treatment of RB-deficient retinoblastoma with Aurora-A kinase inhibitor","volume":"38","author":"Yang","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.ajpath.2024.05.006_bib61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/cam4.1010","article-title":"Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma","volume":"6","author":"Ewens","year":"2017","journal-title":"Cancer Med"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024002050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024002050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:10:16Z","timestamp":1762081816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944024002050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0002944024002050"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.05.006","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aurora Kinase A Is Overexpressed in Human Retinoblastoma and Correlates with Histopathologic High-Risk Factors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}